IP Library Granted Patent US 6,966,905
Granted Patent B2
US 6,966,905 · App. 10/718,980 · Granted Nov 22, 2005

Eye position control monitor for laser vision correction

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,966,905
App. No.
10/718,980
Granted
Nov 22, 2005
Kind
B2
Abstract

A system for spatially stabilizing a base point on the optical axis of a patient's eye, for photoablation of the cornea, includes an optical element for identifying the base point. The system also includes an illumination source which is a fixation point for the eye. Movement of the illumination source induces a saccadic movement of the eye wherein the optical axis of the eye moves from a first orientation to a second orientation. Following the saccadic movement of the eye there is a latency period during which the base point, and hence the eye, is substantially stabilized. Movement of the light source is timed to coincide the latency period with the resting period of the patient's heartbeat sequence, and the relaxation period of the patient's respiration cycle. During the latency period, photoablation is accomplished by directing a train of laser pulses from a laser source into the corneal tissue.

Claims (37)

1. A system for spatially stabilizing a selected base point on the optical axis of an eye of a patient, following a saccadic movement of said eye, which comprises:

an optical means for identifying said base point; and

an illumination means, with means for moving illumination from said illumination means from a first position to a second position, at a distance from said eye, for causing said optical axis of said eye to respectively move from a first orientation to a second orientation to stimulate a saccadic movement of said eye, with a subsequent latency period wherein said selected base point is substantially stabilized.

2. A system as recited in claim 1 further comprising:

a means for determining a resting period in a heartbeat sequence and a relaxation period in a respiration cycle of said patient; and

a computer controller in electronic communication with said determining means for coinciding said resting period and said relaxation period with said latency period to further substantially stabilize said base point during said latency period.

3. A system as recited in claim 2 wherein said determining means is a confocal arrangement.

4. A system as recited in claim 1 wherein said illumination means is a light source for establishing a fixation point and further wherein said fixation point is moved by said moving means through an arc of approximately five degrees to move said optical axis of said eye from said first orientation to said second orientation.

5. A system as recited in claim 1 further comprising:

a laser source for generating a train of laser pulses; and

a guidance optic for directing said train of laser pulses toward said eye for photoablating corneal tissue of said eye during said latency period.

6. A system as recited in claim 5 which further comprises a means for verifying the alignment of the optical axis of the eye immediately prior to said photoablating of said corneal tissue.

7. A system as recited in claim 5 wherein said train of laser pulses is approximately 1500 pulses.

8. A system as recited in claim 1 wherein said optical means includes a confocal arrangement to ascertain the focal point of the specular reflection of said illumination means from the anterior surface of said eye.

9. A system as recited in claim 1 further comprising a wavefront sensor to identify said base point.

10. A system as recited in claim 9 wherein the wavefront sensor consists of:

a wavefront analyzer; and

an active mirror.

11. A method for spatially stabilizing a selected base point on an optical axis of an eye of a patient following a saccadic movement of said eye which comprises the steps of:

identifying a base point on said optical axis of said eye; and

moving an illumination means to cause said optical axis of said eye to move from a first orientation to a second orientation, for stimulating a saccadic movement of said eye, with a subsequent latency period wherein said selected base point is substantially stabilized.

12. A method as recited in claim 11 further comprising the steps of:

determining a resting period in a heartbeat sequence of the patient;

determining a relaxation period in a respiration cycle of the patient; and

coinciding said resting period and said relaxation period with said latency period to further substantially stabilize said base point during said latency period.

13. A method as recited in claim 12 wherein said resting period and said relaxation period are determined using a confocal arrangement.

14. A method as recited in claim 11 wherein said illumination means is a light source for establishing a fixation point and further wherein said fixation point is moved through an arc of approximately five degrees to move said optical axis of said eye from said first orientation to said second orientation.

15. A method as recited in claim 11 further comprising the steps of:

generating a train of laser pulses; and

directing said train of laser pulses into said eye during said latency period for photoablating corneal tissue of said eye.

16. A method as recited in claim 15 wherein said train of laser pulses is approximately 1500 pulses.

17. A method as recited in claim 15 which further comprises the step of verifying the alignment of the optical axis of the eye immediately prior to said photoablating of said corneal tissue.

18. A method as recited in claim 11 wherein said base point is identified using a confocal arrangement to ascertain the focal point of the specular reflection of said illumination means from the anterior surface of said eye.

19. A method as recited in claim 11 wherein the said base point is identified using a wavefront sensor.

20. A method as recited in claim 19 wherein said wavefront sensor consists of:

a wavefront analyzer; and

an active mirror.

Assignments (17)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: TECHNOLAS PERFECT VISION GMBH; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061884/0514 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 036400/0711) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061775/0826 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →
SECURITY AGREEMENT Recorded Aug 20, 2015
From: TECHNOLAS PERFECT VISION GMBH; DR. GERHARD MANN CHEM-PHARM. FABRIK GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036400/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2009
From: 20/10 PERFECT VISION AG
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 023510/0024 →
CHANGE OF NAME Recorded Aug 10, 2009
From: 20/10 PERFECT VISION OPERATIONS GMBH
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 023065/0970 →
CHANGE OF NAME Recorded Aug 6, 2009
From: 20/10 PERFECT VISION AG
To: 20/10 PERFECT VISION OPERATIONS GMBH
Reel/Frame 023065/0012 →
CHANGE OF NAME Recorded Aug 5, 2009
From: 20/10 PERFECT VISION OPTISCHE GERAETE GMBH
To: 20/10 PERFECT VISION AG
Reel/Frame 023056/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2004
From: BILLE, JOSEF
To: 20/10 PERFECT VISION OPTISCHE GERAETE GMBH
Reel/Frame 015143/0311 →